A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

NCT04293185 · clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Genetix Biotherapeutics Inc.